Novo Nordisk Competition -2.3% as GLP-1 Pressure Builds
Can Novo Nordisk Competition derail the obesity leader’s comeback before oral Wegovy and Medicare access have a chance to matter? Maik Kemper Editor in Chief Novo Nordisk A/S’s…
Novo Nordisk Wegovy Faces a Warning in the Obesity Race
Can Novo Nordisk Wegovy regain momentum fast enough to challenge Eli Lilly before the next wave of obesity drugs resets the market? Maik Kemper Editor in Chief Oral…
Novo Nordisk Wegovy Trial Drives 4.2% Stock Surge
Can the Novo Nordisk Wegovy Trial strengthen its obesity lead just as Wall Street starts pricing in the next GLP-1 combination wave? Maik Kemper Editor in Chief Combination…
Novo Nordisk FDA Compounding +4.8% Surge Shakes GLP‑1 Rivals
Will the Novo Nordisk FDA Compounding crackdown finally shut down GLP‑1 copycats and supercharge the branded obesity drug boom? Maik Kemper Editor in Chief When FDA‑approved drugs are…
Eli Lilly GLP-1 pill Foundayo: Can the Boom Last?
Can the new Eli Lilly GLP-1 pill Foundayo justify the stock’s rich valuation and extend its obesity drug dominance? Maik Kemper Editor in Chief Conclusion Overall, the Eli…
Eli Lilly Weight-Loss Strategy vs Novo: Price War Shock
Can the Eli Lilly Weight-Loss Strategy stay on top as Novo Nordisk slashes prices and AI reshapes the obesity drug race? Maik Kemper Editor in Chief Conclusion In…